Nouscom closed a $135 million Series D to advance its NOUS-209 cancer immunotherapy through a global clinical trial.
- Amount
- $135M
- Stage
- Series D
- Announced
- 19 October 2026
- Leads
- M Ventures, Revelation Partners
- Other investors
- Angelini Industries, Angelini Investments, European Investment Bank, Aurea, Neva SGR, 5AM Ventures, Andera Partners, Angelini Ventures, Bpifrance, CDP Venture Capital
- Use of funds
- Advance NOUS-209 through a single global registration-enabling clinical trial for cancer interception in Lynch Syndrome carriers.
- Checked
- Amount and date matched across 3 press sources